At the conclusion of this conference the participants will be able to:

• Describe the evolution of BPH/LUTS understanding from a single-organ obstruction model to a systemic condition involving metabolic, inflammatory, and neurogenic factors
• Compare the contemporary BPH/LUTS diagnostic toolkit including IPSS, uroflowmetry, PSA kinetics, prostate imaging (TRUS to mpMRI), and pressure-flow urodynamics
• Outline the pharmacologic management of BPH/LUTS including alpha-blockers, 5-ARIs, combination therapy (MTOPS/CombAT evidence), PDE5 inhibitors, and beta-3 agonists
• Evaluate the evidence base, indications, and limitations for contemporary MISTs including UroLift, Rezum, Aquablation, and Optilume
• Apply evidence-based shared decision-making to match BPH/LUTS interventions to patient anatomy (prostate size, median lobe), values (ejaculatory preservation), and clinical context
• Discuss the role of AI in healthcare innovation, including safety limitations demonstrated by the Nature Medicine ChatGPT Health evaluation (52% emergency under-triage), and the need for independent clinical guardrails
• Describe the men's health center model integrating urology with endocrinology, cardiology, mental health, and primary care for comprehensive longitudinal BPH/LUTS management.